Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and detailed treatment, introduced the Respiratory Diseases-Only Research Practice (RUO) Panel.
Image credit: Owlstone Medical
The now-commercially available respiratory biomarker panel is intended to support a study to differentiate between different types of chronic airway diseases including asthma, lung disease- chronic obstructive pulmonary disease (COPD), and idiopathic lung fibrosis (IPF), and to provide better therapeutic treatment. decision making and analysis.
The Owlstone Medical Respiratory Diseases RUO Panel is made up of a set of volatile organic compounds (VOCs) that have been linked to inflammatory respiratory diseases, and can be easily assembled on breath to allow disease biology in the lungs identified by noninvasive sampling. the air routes.
Available as an early result of the Company’s experimental development process and supported by scientific publications and Breath Biopsy user survey data, the Panel will initially be offered for Research Use only as part of the expanded Breath Biopsy Products and Services. offers to supplement the OMNI Breath Biopsy. Assay. It will be used by pharmacological and academic / clinical research delegates to support therapeutic development by identifying disease endotypes and monitoring response to treatment, and to better understand the onset, development, and progression of disease. . Building on this Panel, it is planned to develop an in vitro diagnostic (IVD) device to support treatment decisions through patient stratification and therapeutic response monitoring.
Chronic airway diseases are caused by a wide range of biological processes that lead to a significant loss in lung function and quality of life. The impact is huge with an estimated 339 million people worldwide suffering from asthma and another 328 million from COPD, which is the third highest cause of death today and is expected to be at level one within 15 years.
Despite their significant differences in underlying causes, these diseases are similar in clinical presentation, making them difficult to find and deliver effective treatments. Unfortunately, there are currently no cost-effective and patient-friendly methods in identifying airway inflammation. This problem is exacerbated by a growing number of drugs that target specific molecular devices, and are therefore effective for a subset of patients but have little or no side effects. others.
It was important in the development of the RUO Respiratory Diseases Panel that user reviews were conducted using the Company’s Biopsy Breath Products and Services. Through 17 separate studies, nearly 4,000 breath samples were examined and the underlying VOCs were found in the Panel. In line with the Company’s approach in selecting the most specific and relevant biomarkers for any application, these were supplemented by the importation of another set of biofuels from the University of Liege that linked specific VOCs with subtypes1 inflammatory.
The RUO Respiratory Diseases Panel is the first to be commercially launched by Owlstone Medical and opens an important new stage in the application of respiration to address areas of high clinical need. Building on our recent news about the use of limonene as an EVOC® probe in NASH / NAFLD, this Panel further confirms our strategy of identifying promising biomarkers from multiple sources including endogenous detection, EVOC probes, and intracellularity. We look forward to advertising further as our robust test line continues to develop. ”
Billy Boyle, co-founder and CEO of Owlstone Medical
Join the upcoming Owlstone Medical webinar January 27th, 2021 – Detection and Clinical Study of Noninvasive Biomarkers Using Biopsy Breath: https://www.owlstonemedical.com/about/events/discovery-non-invasive- biomarkers /